PDF herunterladen
Aktuelle Rheumatologie 2024; 49(02): 103-109
DOI: 10.1055/a-2215-0830
Übersichtsarbeit

Lyme-Borreliose und Lyme-Arthritis

Lyme borreliosis and Lyme arthritis
Gernot Keyßer
1   Department für Innere Medizin, Klinik und Poliklinik für Innere Medizin II, Universitätsklinikum Halle (Saale), Halle (Saale), Germany
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Die Lyme-Arthritis stellt eine Übergangsform zwischen infektiös-bakteriellen und reaktiven Arthritiden dar. Auslöser sind Borrelien, eine aus mehreren Unterarten bestehende Spezies aus der Familie der Spirochäten. Die Erreger werden i.d.R. durch Stiche der Schildzecken-Gattung Ixodes übertragen und verursachen akute und chronische Manifestationen an Haut, Nervensystem, Gelenken und – seltener – an inneren Organen. Die Behandlung der akuten Lyme-Arthritis erfolgt durch Antibiotika wie Doxycyclin, Amoxizillin und Ceftriaxon. Die chronische Lyme-Arthritis nach erfolgloser Antibiotikatherapie ist ein vielschichtiges, schlecht charakterisiertes und umstrittenes Krankheitsbild, welches in erster Linie Anlass zur Überprüfung der Diagnose geben sollte. Von multiplen Antibiotikazyklen profitieren die Betroffenen nicht.

Abstract

Lyme arthritis is an entity that stands between infectious bacterial arthritis and reactive arthritis. The disease is caused by Borrelia, a species of bacteria that comprises several subspecies and belongs to the family of spirochetes. These bacteria, which are transmitted by bites of ticks of the genus ixodes, can cause acute and chronic manifestations in the skin, the nervous system and the joints. Acute Lyme arthritis is treated with antibiotics such as doxycycline, amoxicillin and ceftriaxone. Chronic Lyme arthritis after unsuccessful treatment with antibiotics is a multi-faceted, ill-characterized and much debated condition. First and foremost, this diagnosis must be assessed critically. Patients affected do not benefit from repeated cycles of antibiotic treatments.

Schlüsselwörter

Borreliose - ixodes ricinus - Lyme-Arthritis - Erythema migrans

Key words

ixodes ricinus - Lyme arthritis - erythema migrans - borreliosis


Publikationsverlauf

Artikel online veröffentlicht:
08. Februar 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Burgdorfer W. Lyme borreliosis: ten years after discovery of the etiologic agent, Borrelia burgdorferi. Infection 1991; 19: 257-262
    CrossrefPubMedSuche in Google Scholar
  • 2 Wilske B. Diagnosis of lyme borreliosis in europe. Vector Borne Zoonotic Dis 2003; 3: 215-227
    CrossrefPubMedSuche in Google Scholar
  • 3 Marques AR. Lyme disease: a review. Curr Allergy Asthma Rep 2010; 10: 13-20
    CrossrefPubMedSuche in Google Scholar
  • 4 Charon NW, Goldstein SF.. Genetics of motility and chemotaxis of a fascinating group of bacteria: the spirochetes. Annu Rev Genet 2002; 36: 47-73
    CrossrefPubMedSuche in Google Scholar
  • 5 Arvikar SL, Steere AC.. Lyme Arthritis. Infect Dis Clin North Am 2022; 36: 563-577
    CrossrefPubMedSuche in Google Scholar
  • 6 Skotarczak B.. Adaptation factors of Borrelia for host and vector. Ann Agric Environ Med 2009; 16: 1-8
    PubMedSuche in Google Scholar
  • 7 Haupl T, Hahn G, Rittig M. et al. Persistence of Borrelia burgdorferi in ligamentous tissue from a patient with chronic Lyme borreliosis. Arthritis Rheum 1993; 36: 1621-1626
    CrossrefPubMedSuche in Google Scholar
  • 8 Coburn J, Garcia B, Hu LT. et al. Lyme Disease Pathogenesis. Curr Issues Mol Biol 2021; 42: 473-518
    CrossrefPubMedSuche in Google Scholar
  • 9 Steere AC.. Lyme disease. N Engl J Med 2001; 345: 115-125
    CrossrefPubMedSuche in Google Scholar
  • 10 Rauter C, Hartung T.. Prevalence of Borrelia burgdorferi sensu lato genospecies in Ixodes ricinus ticks in Europe: a metaanalysis. Appl Environ Microbiol 2005; 71: 7203-7216
    CrossrefPubMedSuche in Google Scholar
  • 11 Baumgarten BU, Rollinghoff M, Bogdan C.. Prevalence of Borrelia burgdorferi and granulocytic and monocytic ehrlichiae in Ixodes ricinus ticks from southern Germany. J Clin Microbiol 1999; 37: 3448-3451
    CrossrefPubMedSuche in Google Scholar
  • 12 Crippa M, Rais O, Gern L.. Investigations on the mode and dynamics of transmission and infectivity of Borrelia burgdorferi sensu stricto and Borrelia afzelii in Ixodes ricinus ticks. Vector Borne Zoonotic Dis 2002; 2: 3-9
    CrossrefPubMedSuche in Google Scholar
  • 13 Kahl O, Janetzki-Mittmann C, Gray JS. et al. Risk of infection with Borrelia burgdorferi sensu lato for a host in relation to the duration of nymphal Ixodes ricinus feeding and the method of tick removal. Zentralbl Bakteriol 1998; 287: 41-52
    CrossrefPubMedSuche in Google Scholar
  • 14 Nahimana I, Gern L, Blanc DS. et al. Risk of Borrelia burgdorferi infection in western Switzerland following a tick bite. Eur J Clin Microbiol Infect Dis 2004; 23: 603-608
    CrossrefPubMedSuche in Google Scholar
  • 15 Heininger U, Zimmermann T, Schoerner C. et al. Tick bite and Lyme borreliosis. An epidemiologic study in the Erlangen area. Monatsschr Kinderheilkd 1993; 141: 874-877
    PubMedSuche in Google Scholar
  • 16 Paul H, Gerth HJ, Ackermann R.. Infectiousness for humans of Ixodes ricinus containing Borrelia burgdorferi. Zentralbl Bakteriol Mikrobiol Hyg A 1987; 263: 473-476
    CrossrefPubMedSuche in Google Scholar
  • 17 Institut RK.. Waldarbeiterstudie Berlin-Brandenburg 2000 zu zeckenübertragenen und anderen Zoonosen. Epidemiologisches Bulletin des RKI 2001; 16: 109-110
    PubMedSuche in Google Scholar
  • 18 Institut RK.. Zur Entwicklung der Lyme-Borreliose-Epidemiologie in Brandenburg. Epidemiologisches Bulletin des RKI 2005; 20: 173-178
    PubMedSuche in Google Scholar
  • 19 Huppertz HI, Bohme M, Standaert SM. et al. Incidence of Lyme borreliosis in the Wurzburg region of Germany. Eur J Clin Microbiol Infect Dis 1999; 18: 697-703
    CrossrefPubMedSuche in Google Scholar
  • 20 Krause A, Fingerle V.. Lyme borreliosis. Z Rheumatol 2009; 68: 239-252 quiz 253-234
    CrossrefPubMedSuche in Google Scholar
  • 21 Steere AC, Schoen RT, Taylor E.. The clinical evolution of Lyme arthritis. Ann Intern Med 1987; 107: 725-731
    CrossrefPubMedSuche in Google Scholar
  • 22 Stanek G, Fingerle V, Hunfeld KP. et al. Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect 2011; 17: 69-79
    CrossrefPubMedSuche in Google Scholar
  • 23 Herzer P, Fingerle V, Pfister HW. et al. Lyme borreliosis. Internist (Berl) 2014; 55: 789-802 quiz 803-784
    CrossrefPubMedSuche in Google Scholar
  • 24 Gaubitz M, Dressler F, Huppertz HI. et al. Diagnosis and treatment of Lyme arthritis. Recommendations of the Pharmacotherapy Commission of the Deutsche Gesellschaft fur Rheumatologie (German Society for Rheumatology). Z Rheumatol 2014; 73: 469-474
    CrossrefPubMedSuche in Google Scholar
  • 25 Rauer S, Kastenbauer S, Hofmann H. et al. Guidelines for diagnosis and treatment in neurology - Lyme neuroborreliosis. Ger Med Sci 2020; 18: Doc03
    CrossrefPubMedSuche in Google Scholar
  • 26 Johnson RC, Kodner C, Russell M.. In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents. Antimicrob Agents Chemother 1987; 31: 164-167
    CrossrefPubMedSuche in Google Scholar
  • 27 Steere AC, Levin RE, Molloy PJ. et al. Treatment of Lyme arthritis. Arthritis Rheum 1994; 37: 878-888
    CrossrefPubMedSuche in Google Scholar
  • 28 Hofmann H, Fingerle V, Hunfeld KP. et al. Cutaneous Lyme borreliosis: Guideline of the German Dermatology Society. Ger Med Sci 2017; 15: Doc14
    CrossrefPubMedSuche in Google Scholar
  • 29 Stupica D, Veluscek M, Blagus R. et al. Oral doxycycline versus intravenous ceftriaxone for treatment of multiple erythema migrans: an open-label alternate-treatment observational trial. J Antimicrob Chemother 2018; 73: 1352-1358
    CrossrefPubMedSuche in Google Scholar
  • 30 Stupica D, Collinet-Adler S, Blagus R. et al. Treatment of erythema migrans with doxycycline for 7 days versus 14 days in Slovenia: a randomised open-label non-inferiority trial. Lancet Infect Dis 2023; 23: 371-379
    CrossrefPubMedSuche in Google Scholar
  • 31 Steere AC, Green J, Schoen RT. et al. Successful parenteral penicillin therapy of established Lyme arthritis. N Engl J Med 1985; 312: 869-874
    CrossrefPubMedSuche in Google Scholar
  • 32 Dattwyler RJ, Halperin JJ, Volkman DJ. et al. Treatment of late Lyme borreliosis – randomised comparison of ceftriaxone and penicillin. Lancet 1988; 1: 1191-1194
    CrossrefPubMedSuche in Google Scholar
  • 33 Eliassen KE, Reiso H, Berild D. et al. Comparison of phenoxymethylpenicillin, amoxicillin, and doxycycline for erythema migrans in general practice. A randomized controlled trial with a 1-year follow-up. Clin Microbiol Infect 2018; 24: 1290-1296
    CrossrefPubMedSuche in Google Scholar
  • 34 Bentas W, Karch H, Huppertz HI.. Lyme arthritis in children and adolescents: outcome 12 months after initiation of antibiotic therapy. J Rheumatol 2000; 27: 2025-2030
    PubMedSuche in Google Scholar
  • 35 Horton DB, Taxter AJ, Davidow AL. et al. Intraarticular Glucocorticoid Injection as Second-line Treatment for Lyme Arthritis in Children. J Rheumatol 2019; 46: 952-959
    CrossrefPubMedSuche in Google Scholar
  • 36 Nimmrich S, Becker I, Horneff G.. Intraarticular corticosteroids in refractory childhood Lyme arthritis. Rheumatol Int 2014; 34: 987-994
    CrossrefPubMedSuche in Google Scholar
  • 37 Ursinus J, Vrijmoeth HD, Harms MG. et al. Prevalence of persistent symptoms after treatment for lyme borreliosis: A prospective observational cohort study. Lancet Reg Health Eur 2021; 6: 100142
    CrossrefPubMedSuche in Google Scholar
  • 38 Feder HM, Johnson BJ, OʼConnell S. et al. A critical appraisal of „chronic Lyme disease“. N Engl J Med 2007; 357: 1422-1430
    CrossrefPubMedSuche in Google Scholar
  • 39 Berende A, ter Hofstede HJ, Vos FJ. et al. Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease. N Engl J Med 2016; 374: 1209-1220
    CrossrefPubMedSuche in Google Scholar
  • 40 Klempner MS, Hu LT, Evans J. et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001; 345: 85-92
    CrossrefPubMedSuche in Google Scholar
  • 41 Krupp LB, Hyman LG, Grimson R. et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology 2003; 60: 1923-1930
    CrossrefPubMedSuche in Google Scholar
  • 42 Harms MG, Hofhuis A, Sprong H. et al. A single dose of doxycycline after an ixodes ricinus tick bite to prevent Lyme borreliosis: An open-label randomized controlled trial. J Infect 2021; 82: 98-104
    CrossrefPubMedSuche in Google Scholar
  • 43 Wressnigg N, Barrett PN, Pollabauer EM. et al. A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu lato. Clin Vaccine Immunol 2014; 21: 1490-1499
    CrossrefPubMedSuche in Google Scholar
  • 44 Mitchell C, Dyer M, Lin FC. et al. Protective Effectiveness of Long-Lasting Permethrin Impregnated Clothing Against Tick Bites in an Endemic Lyme Disease Setting: A Randomized Control Trial Among Outdoor Workers. J Med Entomol 2020; 57: 1532-1538
    CrossrefPubMedSuche in Google Scholar